Drug Trial Radar · NCT05597280
Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy
Last checked: Nov 19, 2026Latest source record: May 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
124,000
Planned (sponsor's estimate)
Start
Mar 22, 2023
Primary completion
Mar 15, 2027
Study completion Mar 15, 2027
Sponsor
- Lead sponsor
- Institute of Tropical Medicine, BelgiumAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 28, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
There will be two study arms. Arm 1 will be the intervention arm in which there will be provided BE-PEP to all persons residing within 100 meters of an index case, to be repeated after four weeks for household contacts. Arm 2 will be the comparator arm in which the WHO recommended standard PEP will be provided, i.e. 10 mg/kg of rifampicin in a single dose. In both arms the investigators will target anyone living within 100 meters of an index case or the entire village if more than 50% are eligible. Provision of BE-PEP will start in 2023 and follow-up will continue until 2026. The main study outcome will be the comparison of leprosy risk in individuals that received BE-PEOPLE standard WHO SDR-PEP versus individuals that received BE-PEP. In addition the investigators will compare the overall leprosy incidence over the follow-up period between the two study arms.
Conditions
- Leprosy
Interventions
BE-PEP BedaquilineDrug
bedaquiline
SDR-PEP RifampicinDrug
SDR-PEP: rifampicin
BE-PEP RifampicinDrug
BE-PEP rifampicin
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate effectiveness of PEP based on a combination of rifampicin and bedaquiline (BE-PEP), in preventing leprosy among contacts of incident cases.Time frame: Through study completion, an average of 4 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fondation Damien
Moroni, Comoros · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.